512O Interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignancies.
Saved in:
| Title: | 512O Interim results from a phase II study of the ATR inhibitor ceralasertib in ARID1A-deficient and ARID1A-intact advanced solid tumor malignancies. |
|---|---|
| Authors: | Aggarwal, R.1 (AUTHOR), Umetsu, S.2 (AUTHOR), Dhawan, M.1 (AUTHOR), Grabowsky, J.3 (AUTHOR), Carnevale, J.1 (AUTHOR), Howell, M.1 (AUTHOR), Wilch, L.1 (AUTHOR), Chapman, J.4 (AUTHOR), Alvarez, E.1 (AUTHOR), Calabrese, S.1 (AUTHOR), Smith, S.5 (AUTHOR), Shah, N.5 (AUTHOR), Dean, E.5 (AUTHOR), Munster, P.1 (AUTHOR), Collisson, E.1 (AUTHOR) |
| Source: | Annals of Oncology. 2021 Supplement 5, Vol. 32, pS583-S583. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2021.08.1034 |
